

Rosetta Genomics Ltd.
Form 6-K
February 15, 2017

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For the Month of February 2017

Commission File Number 001-33042

Rosetta Genomics Ltd.
(Translation of registrant's name into English)

**10 Plaut Street, Science Park
Rehovot 76706, Israel**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Edgar Filing: Rosetta Genomics Ltd. - Form 6-K

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Rosetta Genomics Ltd.

Dganit Bar, Ph.D., has notified Rosetta Genomics Ltd. (the “Company”) that she is resigning as Chief Scientific Officer of the Company, effective March 14, 2017, to assume the Chief Executive Officer position at a company focused on therapeutics.

The information contained in this Report is hereby incorporated by reference into the Company’s Registration Statements on Form F-3, File Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338, 333-207697, 333-210366 and 333-214981.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ROSETTA GENOMICS
LTD.**

Date: February 15, 2017 By: /s/ Ron Kalfus

Ron Kalfus

Chief Financial Officer